TRUMENBA® Adverse Reactions

(Meningococcal Group B Vaccine)

6 ADVERSE REACTIONS

In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at the injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in clinical practice.

The safety of Trumenba was evaluated in 16,284 subjects 10 through 25 years of age in 12 clinical studies (9 randomized controlled and 3 supportive non-controlled studies) conducted in the U.S., Europe, Canada, Chile, and Australia. A total of 11,991 subjects 10 through 18 years of age, and 4,293 subjects 19 through 25 years of age received at least one dose of Trumenba. A total of 5,501 subjects 10 through 25 years of age in the control groups received saline placebo and/or one of the following vaccine(s): Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant (HPV4) (Merck & Co., Inc.); Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) (Sanofi Pasteur Ltd.); Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MenACWY) (Sanofi Pasteur Inc.); a non-U.S. licensed reduced diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated polio virus vaccine (dTaP-IPV) (Sanofi Pasteur, Inc.); Hepatitis A Vaccine (HAV) (GlaxoSmithKline Biologicals).

The safety evaluation in the clinical studies included an assessment of: (1) solicited local and systemic reactions, and use of antipyretic medication after each vaccination in an electronic diary maintained by the subject or the subject's parent/legal guardian and (2) spontaneous reports of adverse events (AEs), including serious adverse events (SAEs), throughout the study (day of vaccination through 1 month or 6 months after the last vaccination, depending on the study and safety parameter).

In controlled studies, demographic characteristics were generally similar with regard to gender, race, and ethnicity among subjects who received Trumenba and those who received control. Among participants in clinical trials B1971009 (Study 1009), B1971016 (Study 1016), and B1971057 (Study 1057), 41.3% to 51.5% were male, 76.1% to 87.3% were White, 8.1% to 20.8% were Black or African-American, <2% were Asian, and 5.8% to 17.1% were Hispanic/Latino.

Solicited Local and Systemic Adverse Reactions

Study 1057 was a randomized, observer-blinded, multicenter trial in the U.S. and Europe. In this study, 1057 subjects 10 through 25 years of age received at least 1 dose of Trumenba on a 0- and 6-month schedule. Trumenba was co-administered with Meningococcal (Groups A, C, Y, W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MenACWY) (GSK Vaccines, SRL) for the first dose.

Study 1009 was a randomized, active-controlled, observer-blinded, multicenter trial in the U.S., Canada, and Europe in which 2,693 subjects 10 through 18 years of age received at least 1 dose of Trumenba on a 0-, 2-, and 6- month schedule. A control group (n=897) received HAV at 0 and 6 months, and saline at 2 months.

Study 1016 was a randomized, placebo-controlled, observer-blinded, multicenter trial in the U.S., Canada, and Europe in which 2,471 subjects 18 through 25 years of age received at least 1 dose of Trumenba and 822 subjects received saline on a 0-, 2,- and 6- month schedule.

Local adverse reactions at the injection site were assessed in the three studies.

Tables 1, 2, and 3 present the percentage and severity of reported local adverse reactions within 7 days following each dose of Trumenba for Study 1057 and following each dose of Trumenba or control (HAV/saline or saline) for Study 1009 and Study 1016, respectively.

In Studies 1009 and 1016, local adverse reactions were reported more frequently following Trumenba compared to control (see Tables 2 and 3, respectively).

Table 1: Percentages of Subjects 10 through 25 Years of Age (Study 1057*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Local ReactionDose 1Dose 2
Trumenba+MenACWY-CRM†Trumenba†
N=1044N=903
*
Study 1057: National Clinical Trial (NCT) number NCT03135834.
†
Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months. Local reactions were recorded at the Trumenba injection site only.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

85.0

82.2

  Mild

41.2

38.9

  Moderate

39.1

37.9

  Severe

4.7

5.4

Redness

  Any§ (≥ 2.5 cm)

16.9

14.7

  Mild

6.8

5.2

  Moderate

8.0

8.4

  Severe

2.0

1.1

Swelling

  Any§ (≥ 2.5 cm)

17.0

14.3

  Mild

9.8

6.4

  Moderate

6.9

7.5

  Severe

0.3

0.3

Table 2: Percentages of Subjects 10 through 18 Years of Age (Study 1009*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†HAV/Saline†Trumenba†HAV/Saline†Trumenba†HAV/Saline†
Local ReactionN=2681N=890N=2545N=843N=2421N=821
*
Study 1009: NCT01830855.
†
Trumenba was administered at 0, 2, and 6 months. HAV was administered at 0 and 6 months and saline was administered at 2 months.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

86.7

47.0

77.7

15.2

76.0

34.0

  Mild

41.1

36.5

39.4

12.3

34.1

23.8

  Moderate

40.7

9.9

33.2

2.7

36.5

9.9

  Severe

5.0

0.6

5.1

0.1

5.4

0.4

Redness

  Any§ (≥ 2.5 cm)

16.2

1.3

12.5

0.6

13.9

1.1

  Mild

5.6

1.2

5.2

0.6

4.9

1.0

  Moderate

8.8

0.1

6.1

0.0

6.8

0.1

  Severe

1.9

0.0

1.1

0.0

2.2

0.0

Swelling

  Any§ (≥ 2.5 cm)

18.0

2.2

13.9

0.6

15.4

0.9

  Mild

8.5

1.8

6.3

0.5

7.9

0.7

  Moderate

8.8

0.4

7.3

0.1

6.8

0.1

  Severe

0.7

0.0

0.2

0.0

0.7

0.0

Table 3: Percentages of Subjects 18 through 25 Years of Age (Study 1016*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†Saline†Trumenba†Saline†Trumenba†Saline†
Local ReactionN=2425N=798N=2076N=706N=1823N=624
*
Study 1016: NCT01352845.
†
Trumenba was administered at 0, 2, and 6 months. Saline was administered at 0, 2, and 6 months.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

84.2

11.8

79.3

7.8

80.4

6.7

  Mild

42.3

10.7

42.2

6.8

36.1

6.4

  Moderate

37.1

1.1

32.7

1.0

38.9

0.3

  Severe

4.8

0.0

4.4

0.0

5.3

0.0

Redness

  Any§ (≥ 2.5 cm)

13.8

0.6

11.8

0.3

17.1

0.2

  Mild

5.8

0.5

4.6

0.1

6.2

0.2

  Moderate

7.1

0.0

6.3

0.0

8.6

0.0

  Severe

0.9

0.1

0.9

0.1

2.3

0.0

Swelling

  Any§ (≥ 2.5 cm)

15.5

0.6

14.0

0.4

16.6

0.3

  Mild

8.5

0.3

7.7

0.3

8.8

0.0

  Moderate

6.8

0.3

6.0

0.1

7.2

0.3

  Severe

0.2

0.1

0.3

0.0

0.5

0.0

In Study 1057, among Trumenba recipients, mean duration of pain was 2.7 days (range 1–17 days) after the first vaccination and 2.7 days (range 1–12 days) after the second vaccination; redness was 2.2 days (range 1–9 days) and 2.4 days (1–11 days), respectively; and swelling was 2.2 days (range 1–17 days) and 2.5 days (range 1–27 days), respectively.

In Study 1009, mean duration of pain was 2.4 to 2.6 days (range 1–17 days), redness was 2.0 to 2.2 days (range 1–12 days) and swelling was 2.0 to 2.1 days (range 1–21 days) for the three-dose series in the Trumenba groups. In Study 1016, mean duration of pain was 2.6 to 2.8 days (range 1–67 days), redness was 2.2 to 2.5 days (range 1–13 days) and swelling was 2.1 to 2.6 days (range 1–70 days) in the Trumenba group.

Tables 4, 5, and 6 present the percentage and severity of reported solicited systemic adverse reactions within 7 days of each dose of Trumenba for Study 1057 and within 7 days of each dose of Trumenba or control (HAV/saline or saline) for Study 1009 and Study 1016, respectively.

Table 4: Percentages of Subjects 10 through 25 Years of Age (Study 1057*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Systemic ReactionDose 1Dose 2
Trumenba+MenACWY-CRM†Trumenba†
N=1044N=903
*
Study 1057: NCT03135834.
†
Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months.
‡
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
#
Mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity).

Fever (≥38°C)

  ≥38.0°C

6.7

3.2

  38.0°C to <38.5°C

4.0

1.9

  38.5°C to <39.0°C

2.1

0.7

  39.0°C to ≤40.0°C

0.6

0.7

  >40.0°C

0.0

0.0

Vomiting ‡

  Any§

3.7

2.8

  Mild

2.9

2.0

  Moderate

0.9

0.8

  Severe

0.0

0.0

Diarrhea

  Any§

14.1

10.6

  Mild

10.7

7.6

  Moderate

3.3

2.5

  Severe

0.1

0.4

Headache#

  Any§

46.5

41.6

  Mild

25.1

23.1

  Moderate

19.0

16.5

  Severe

2.4

2.0

Fatigue#

  Any§

51.9

45.2

  Mild

25.4

23.0

  Moderate

23.7

19.2

  Severe

2.9

3.0

Chills#

  Any§

18.5

18.5

  Mild

11.5

11.6

  Moderate

5.7

6.2

  Severe

1.2

0.7

Muscle pain (other than muscle pain at the injection site)#

  Any§

28.4

21.4

  Mild

15.8

11.5

  Moderate

11.6

7.8

  Severe

1.1

2.1

Joint pain#

  Any§

19.6

18.7

  Mild

10.2

11.2

  Moderate

8.6

6.5

  Severe

0.8

1.0

Use of antipyretic medication

18.6

14.4

Table 5: Percentages of Subjects 10 through 18 Years of Age (Study 1009*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†HAV/Saline†Trumenba†HAV/Saline†Trumenba†HAV/Saline†
Systemic ReactionN=2681N=890N=2545N=843N=2421N=821
*
Study 1009: NCT01830855.
†
Trumenba was administered at 0, 2, and 6 months. HAV was administered at 0 and 6 months and saline was administered at 2 months.
‡
Study 1009: Fever (≥38°C): N=2679, 2540, and 2414 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=890, 840, and 819 for HAV/saline at Dose 1, Dose 2, and Dose 3, respectively.
§
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
#
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
Þ
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).

Fever (≥38°C)‡

  ≥38.0°C

6.4

1.9

2.0

1.5

2.7

2.3

  38.0°C to <38.5°C

4.0

1.3

1.2

0.7

1.8

1.3

  38.5°C to <39.0°C

1.9

0.3

0.7

0.7

0.6

0.4

  39.0°C to ≤40.0°C

0.5

0.2

0.1

0.1

0.3

0.5

  >40.0°C

0.0

0.0

0.0

0.0

0.0

0.1

Vomiting§

  Any

3.7

1.9

2.2

1.4

1.7

2.2

  Mild

2.8

1.7

1.7

1.1

1.4

1.7

  Moderate

0.9

0.2

0.4

0.4

0.3

0.5

  Severe

0.0

0.0

0.0

0.0

0.0

0.0

Diarrhea#

  Any

10.6

12.1

7.6

9.1

7.7

7.6

  Mild

9.1

10.9

6.2

7.6

6.4

6.2

  Moderate

1.3

1.1

1.3

1.2

1.0

1.1

  Severe

0.3

0.1

0.1

0.4

0.3

0.2

HeadacheÞ

  Any

51.8

37.2

37.8

28.1

35.4

24.8

  Mild

28.7

24.0

20.2

15.7

18.9

13.5

  Moderate

21.0

12.5

16.0

10.9

15.2

10.4

  Severe

2.2

0.7

1.7

1.5

1.3

1.0

FatigueÞ

  Any

54.0

40.3

38.3

26.3

35.9

24.4

  Mild

27.8

23.5

20.6

13.2

18.4

13.5

  Moderate

23.2

15.2

15.8

11.7

15.2

10.0

  Severe

3.0

1.7

1.9

1.4

2.3

0.9

ChillsÞ

  Any

25.3

17.2

16.0

10.3

13.1

8.3

  Mild

16.2

13.3

10.6

8.1

8.7

6.5

  Moderate

8.0

3.5

4.8

1.8

3.8

1.7

  Severe

1.2

0.4

0.6

0.5

0.5

0.1

Muscle pain (other than muscle pain at the injection site)Þ

  Any

24.4

19.2

17.8

10.3

17.6

11.1

  Mild

13.2

13.5

8.7

5.2

9.5

6.6

  Moderate

10.1

5.4

7.9

4.5

7.2

4.3

  Severe

1.2

0.3

1.2

0.6

0.8

0.2

Joint painÞ

  Any

21.9

13.6

16.7

9.1

16.0

8.9

  Mild

11.8

8.3

8.4

5.0

8.9

5.5

  Moderate

8.7

4.6

7.5

3.4

5.9

3.0

  Severe

1.4

0.7

0.8

0.7

1.2

0.4

Use of antipyretic medication

20.7

10.4

13.6

8.9

12.7

6.8

Table 6: Percentages of Subjects 18 through 25 Years of Age (Study 1016*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†Saline†Trumenba†Saline†Trumenba†Saline†
Systemic ReactionN=2425N=798N=2076N=706N=1823N=624
*
Study 1016: NCT01352845.
†
Trumenba was administered at 0, 2, and 6 months. Saline was administered at 0, 2, and 6 months.
‡
Study 1016: Fever (≥38°C): N=2415, 2067, and 1814 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=796, 705, and 621 for saline at Dose 1, Dose 2, and Dose 3, respectively.
§
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
#
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
Þ
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).

Fever (≥38°C)‡

  ≥38.0°C

2.4

0.6

1.2

1.0

2.0

0.6

  38.0°C to <38.5°C

1.6

0.4

0.7

0.6

1.4

0.5

  38.5°C to <39.0°C

0.7

0.0

0.4

0.3

0.4

0.2

  39.0°C to ≤40.0°C

0.0

0.3

0.1

0.1

0.1

0.0

  >40.0°C

0.0

0.0

0.0

0.0

0.1

0.0

Vomiting§

  Any

2.6

2.1

2.1

1.6

2.0

1.4

  Mild

2.2

2.1

1.6

1.3

1.8

1.1

  Moderate

0.4

0.0

0.5

0.3

0.2

0.3

  Severe

0.0

0.0

0.0

0.0

0.0

0.0

Diarrhea#

  Any

12.7

11.8

8.6

8.1

7.5

6.9

  Mild

10.2

9.8

6.4

4.7

6.1

5.3

  Moderate

2.4

1.9

1.7

2.8

1.2

1.3

  Severe

0.2

0.1

0.5

0.6

0.2

0.3

HeadacheÞ

  Any

43.9

36.2

33.1

24.9

32.5

21.6

  Mild

24.3

22.1

18.4

13.6

17.6

12.5

  Moderate

17.9

13.5

13.3

10.1

13.3

8.3

  Severe

1.6

0.6

1.4

1.3

1.6

0.8

FatigueÞ

  Any

50.9

39.8

39.2

27.3

39.3

24.5

  Mild

25.4

23.2

20.6

13.9

18.9

13.1

  Moderate

22.1

15.8

16.4

11.5

18.8

9.6

  Severe

3.4

0.9

2.2

2.0

1.6

1.8

ChillsÞ

  Any

18.1

9.8

12.4

8.5

12.6

6.4

  Mild

12.0

8.1

8.1

6.9

7.7

4.3

  Moderate

4.9

1.6

3.5

1.6

4.2

2.1

  Severe

1.1

0.0

0.8

0.0

0.8

0.0

Muscle pain (other than muscle pain at the injection site)Þ

  Any

25.9

14.5

15.6

8.5

16.9

7.5

  Mild

13.0

9.6

7.6

5.8

8.9

4.5

  Moderate

11.3

4.4

7.1

2.3

6.8

2.9

  Severe

1.6

0.5

0.8

0.4

1.2

0.2

Joint painÞ

  Any

19.6

10.9

15.1

6.5

12.6

5.3

  Mild

10.3

6.9

8.1

3.7

6.6

2.9

  Moderate

7.9

3.5

6.2

2.5

5.4

2.4

  Severe

1.4

0.5

0.9

0.3

0.6

0.0

Use of antipyretic medication

13.4

8.9

12.3

7.6

12.8

6.6

In three early phase studies in which it was solicited, nausea was reported in up to 24% of adolescents.

The frequencies of adverse reactions were highest after the first dose regardless of the schedule. After subsequent doses, the frequencies of adverse reactions were similar regardless of dose number and schedule.

Serious Adverse Events

Among the 8 controlled studies investigating the three-dose (0, 1–2, and 6 months) schedule (Trumenba N=13,275, control N=5,501), SAEs were reported by 213 (1.6%) subjects and by 106 (1.9%) subjects who received at least one dose of Trumenba or control, respectively.

Non-serious Adverse Events

Among the 8 controlled studies investigating the three-dose (0, 1–2, and 6 months) schedule (Trumenba N=13,275, control N=5,501), AEs that occurred within 30 days of vaccination were reported in 4,056 (30.6%) subjects who received at least one dose of Trumenba and 1,539 (28.0%) subjects in the control group who received at least one dose. AEs that occurred at a frequency of at least 2% and were more frequently observed in subjects who received Trumenba than subjects in the control group were injection site pain, fever, and headache.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Trumenba. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure.

Immune System Disorders: Hypersensitivity reactions, including anaphylactic reactions.

Nervous system disorder: Syncope (fainting).

Find TRUMENBA® medical information:

Find TRUMENBA® medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

TRUMENBA® Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Adverse Reactions

6 ADVERSE REACTIONS

In clinical studies, the most common solicited adverse reactions in adolescents and young adults were pain at the injection site (≥85%), fatigue (≥60%), headache (≥55%), and muscle pain (≥35%).

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in clinical practice.

The safety of Trumenba was evaluated in 16,284 subjects 10 through 25 years of age in 12 clinical studies (9 randomized controlled and 3 supportive non-controlled studies) conducted in the U.S., Europe, Canada, Chile, and Australia. A total of 11,991 subjects 10 through 18 years of age, and 4,293 subjects 19 through 25 years of age received at least one dose of Trumenba. A total of 5,501 subjects 10 through 25 years of age in the control groups received saline placebo and/or one of the following vaccine(s): Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant (HPV4) (Merck & Co., Inc.); Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap) (Sanofi Pasteur Ltd.); Meningococcal (Serogroups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (MenACWY) (Sanofi Pasteur Inc.); a non-U.S. licensed reduced diphtheria toxoid, tetanus toxoid, acellular pertussis and inactivated polio virus vaccine (dTaP-IPV) (Sanofi Pasteur, Inc.); Hepatitis A Vaccine (HAV) (GlaxoSmithKline Biologicals).

The safety evaluation in the clinical studies included an assessment of: (1) solicited local and systemic reactions, and use of antipyretic medication after each vaccination in an electronic diary maintained by the subject or the subject's parent/legal guardian and (2) spontaneous reports of adverse events (AEs), including serious adverse events (SAEs), throughout the study (day of vaccination through 1 month or 6 months after the last vaccination, depending on the study and safety parameter).

In controlled studies, demographic characteristics were generally similar with regard to gender, race, and ethnicity among subjects who received Trumenba and those who received control. Among participants in clinical trials B1971009 (Study 1009), B1971016 (Study 1016), and B1971057 (Study 1057), 41.3% to 51.5% were male, 76.1% to 87.3% were White, 8.1% to 20.8% were Black or African-American, <2% were Asian, and 5.8% to 17.1% were Hispanic/Latino.

Solicited Local and Systemic Adverse Reactions

Study 1057 was a randomized, observer-blinded, multicenter trial in the U.S. and Europe. In this study, 1057 subjects 10 through 25 years of age received at least 1 dose of Trumenba on a 0- and 6-month schedule. Trumenba was co-administered with Meningococcal (Groups A, C, Y, W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine (MenACWY) (GSK Vaccines, SRL) for the first dose.

Study 1009 was a randomized, active-controlled, observer-blinded, multicenter trial in the U.S., Canada, and Europe in which 2,693 subjects 10 through 18 years of age received at least 1 dose of Trumenba on a 0-, 2-, and 6- month schedule. A control group (n=897) received HAV at 0 and 6 months, and saline at 2 months.

Study 1016 was a randomized, placebo-controlled, observer-blinded, multicenter trial in the U.S., Canada, and Europe in which 2,471 subjects 18 through 25 years of age received at least 1 dose of Trumenba and 822 subjects received saline on a 0-, 2,- and 6- month schedule.

Local adverse reactions at the injection site were assessed in the three studies.

Tables 1, 2, and 3 present the percentage and severity of reported local adverse reactions within 7 days following each dose of Trumenba for Study 1057 and following each dose of Trumenba or control (HAV/saline or saline) for Study 1009 and Study 1016, respectively.

In Studies 1009 and 1016, local adverse reactions were reported more frequently following Trumenba compared to control (see Tables 2 and 3, respectively).

Table 1: Percentages of Subjects 10 through 25 Years of Age (Study 1057*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Local ReactionDose 1Dose 2
Trumenba+MenACWY-CRM†Trumenba†
N=1044N=903
*
Study 1057: National Clinical Trial (NCT) number NCT03135834.
†
Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months. Local reactions were recorded at the Trumenba injection site only.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

85.0

82.2

  Mild

41.2

38.9

  Moderate

39.1

37.9

  Severe

4.7

5.4

Redness

  Any§ (≥ 2.5 cm)

16.9

14.7

  Mild

6.8

5.2

  Moderate

8.0

8.4

  Severe

2.0

1.1

Swelling

  Any§ (≥ 2.5 cm)

17.0

14.3

  Mild

9.8

6.4

  Moderate

6.9

7.5

  Severe

0.3

0.3

Table 2: Percentages of Subjects 10 through 18 Years of Age (Study 1009*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†HAV/Saline†Trumenba†HAV/Saline†Trumenba†HAV/Saline†
Local ReactionN=2681N=890N=2545N=843N=2421N=821
*
Study 1009: NCT01830855.
†
Trumenba was administered at 0, 2, and 6 months. HAV was administered at 0 and 6 months and saline was administered at 2 months.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

86.7

47.0

77.7

15.2

76.0

34.0

  Mild

41.1

36.5

39.4

12.3

34.1

23.8

  Moderate

40.7

9.9

33.2

2.7

36.5

9.9

  Severe

5.0

0.6

5.1

0.1

5.4

0.4

Redness

  Any§ (≥ 2.5 cm)

16.2

1.3

12.5

0.6

13.9

1.1

  Mild

5.6

1.2

5.2

0.6

4.9

1.0

  Moderate

8.8

0.1

6.1

0.0

6.8

0.1

  Severe

1.9

0.0

1.1

0.0

2.2

0.0

Swelling

  Any§ (≥ 2.5 cm)

18.0

2.2

13.9

0.6

15.4

0.9

  Mild

8.5

1.8

6.3

0.5

7.9

0.7

  Moderate

8.8

0.4

7.3

0.1

6.8

0.1

  Severe

0.7

0.0

0.2

0.0

0.7

0.0

Table 3: Percentages of Subjects 18 through 25 Years of Age (Study 1016*) Reporting Local Adverse Reactions Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†Saline†Trumenba†Saline†Trumenba†Saline†
Local ReactionN=2425N=798N=2076N=706N=1823N=624
*
Study 1016: NCT01352845.
†
Trumenba was administered at 0, 2, and 6 months. Saline was administered at 0, 2, and 6 months.
‡
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2.5–5.0 cm); moderate (>5.0–10.0 cm); severe (>10.0 cm).

Pain‡

  Any§

84.2

11.8

79.3

7.8

80.4

6.7

  Mild

42.3

10.7

42.2

6.8

36.1

6.4

  Moderate

37.1

1.1

32.7

1.0

38.9

0.3

  Severe

4.8

0.0

4.4

0.0

5.3

0.0

Redness

  Any§ (≥ 2.5 cm)

13.8

0.6

11.8

0.3

17.1

0.2

  Mild

5.8

0.5

4.6

0.1

6.2

0.2

  Moderate

7.1

0.0

6.3

0.0

8.6

0.0

  Severe

0.9

0.1

0.9

0.1

2.3

0.0

Swelling

  Any§ (≥ 2.5 cm)

15.5

0.6

14.0

0.4

16.6

0.3

  Mild

8.5

0.3

7.7

0.3

8.8

0.0

  Moderate

6.8

0.3

6.0

0.1

7.2

0.3

  Severe

0.2

0.1

0.3

0.0

0.5

0.0

In Study 1057, among Trumenba recipients, mean duration of pain was 2.7 days (range 1–17 days) after the first vaccination and 2.7 days (range 1–12 days) after the second vaccination; redness was 2.2 days (range 1–9 days) and 2.4 days (1–11 days), respectively; and swelling was 2.2 days (range 1–17 days) and 2.5 days (range 1–27 days), respectively.

In Study 1009, mean duration of pain was 2.4 to 2.6 days (range 1–17 days), redness was 2.0 to 2.2 days (range 1–12 days) and swelling was 2.0 to 2.1 days (range 1–21 days) for the three-dose series in the Trumenba groups. In Study 1016, mean duration of pain was 2.6 to 2.8 days (range 1–67 days), redness was 2.2 to 2.5 days (range 1–13 days) and swelling was 2.1 to 2.6 days (range 1–70 days) in the Trumenba group.

Tables 4, 5, and 6 present the percentage and severity of reported solicited systemic adverse reactions within 7 days of each dose of Trumenba for Study 1057 and within 7 days of each dose of Trumenba or control (HAV/saline or saline) for Study 1009 and Study 1016, respectively.

Table 4: Percentages of Subjects 10 through 25 Years of Age (Study 1057*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Systemic ReactionDose 1Dose 2
Trumenba+MenACWY-CRM†Trumenba†
N=1044N=903
*
Study 1057: NCT03135834.
†
Trumenba and MenACWY-CRM were administered at 0 month followed by Trumenba alone at 6 months.
‡
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
§
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
#
Mild (does not interfere with activity); moderate (some interference with activity); severe (prevents daily routine activity).

Fever (≥38°C)

  ≥38.0°C

6.7

3.2

  38.0°C to <38.5°C

4.0

1.9

  38.5°C to <39.0°C

2.1

0.7

  39.0°C to ≤40.0°C

0.6

0.7

  >40.0°C

0.0

0.0

Vomiting ‡

  Any§

3.7

2.8

  Mild

2.9

2.0

  Moderate

0.9

0.8

  Severe

0.0

0.0

Diarrhea

  Any§

14.1

10.6

  Mild

10.7

7.6

  Moderate

3.3

2.5

  Severe

0.1

0.4

Headache#

  Any§

46.5

41.6

  Mild

25.1

23.1

  Moderate

19.0

16.5

  Severe

2.4

2.0

Fatigue#

  Any§

51.9

45.2

  Mild

25.4

23.0

  Moderate

23.7

19.2

  Severe

2.9

3.0

Chills#

  Any§

18.5

18.5

  Mild

11.5

11.6

  Moderate

5.7

6.2

  Severe

1.2

0.7

Muscle pain (other than muscle pain at the injection site)#

  Any§

28.4

21.4

  Mild

15.8

11.5

  Moderate

11.6

7.8

  Severe

1.1

2.1

Joint pain#

  Any§

19.6

18.7

  Mild

10.2

11.2

  Moderate

8.6

6.5

  Severe

0.8

1.0

Use of antipyretic medication

18.6

14.4

Table 5: Percentages of Subjects 10 through 18 Years of Age (Study 1009*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†HAV/Saline†Trumenba†HAV/Saline†Trumenba†HAV/Saline†
Systemic ReactionN=2681N=890N=2545N=843N=2421N=821
*
Study 1009: NCT01830855.
†
Trumenba was administered at 0, 2, and 6 months. HAV was administered at 0 and 6 months and saline was administered at 2 months.
‡
Study 1009: Fever (≥38°C): N=2679, 2540, and 2414 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=890, 840, and 819 for HAV/saline at Dose 1, Dose 2, and Dose 3, respectively.
§
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
#
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
Þ
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).

Fever (≥38°C)‡

  ≥38.0°C

6.4

1.9

2.0

1.5

2.7

2.3

  38.0°C to <38.5°C

4.0

1.3

1.2

0.7

1.8

1.3

  38.5°C to <39.0°C

1.9

0.3

0.7

0.7

0.6

0.4

  39.0°C to ≤40.0°C

0.5

0.2

0.1

0.1

0.3

0.5

  >40.0°C

0.0

0.0

0.0

0.0

0.0

0.1

Vomiting§

  Any

3.7

1.9

2.2

1.4

1.7

2.2

  Mild

2.8

1.7

1.7

1.1

1.4

1.7

  Moderate

0.9

0.2

0.4

0.4

0.3

0.5

  Severe

0.0

0.0

0.0

0.0

0.0

0.0

Diarrhea#

  Any

10.6

12.1

7.6

9.1

7.7

7.6

  Mild

9.1

10.9

6.2

7.6

6.4

6.2

  Moderate

1.3

1.1

1.3

1.2

1.0

1.1

  Severe

0.3

0.1

0.1

0.4

0.3

0.2

HeadacheÞ

  Any

51.8

37.2

37.8

28.1

35.4

24.8

  Mild

28.7

24.0

20.2

15.7

18.9

13.5

  Moderate

21.0

12.5

16.0

10.9

15.2

10.4

  Severe

2.2

0.7

1.7

1.5

1.3

1.0

FatigueÞ

  Any

54.0

40.3

38.3

26.3

35.9

24.4

  Mild

27.8

23.5

20.6

13.2

18.4

13.5

  Moderate

23.2

15.2

15.8

11.7

15.2

10.0

  Severe

3.0

1.7

1.9

1.4

2.3

0.9

ChillsÞ

  Any

25.3

17.2

16.0

10.3

13.1

8.3

  Mild

16.2

13.3

10.6

8.1

8.7

6.5

  Moderate

8.0

3.5

4.8

1.8

3.8

1.7

  Severe

1.2

0.4

0.6

0.5

0.5

0.1

Muscle pain (other than muscle pain at the injection site)Þ

  Any

24.4

19.2

17.8

10.3

17.6

11.1

  Mild

13.2

13.5

8.7

5.2

9.5

6.6

  Moderate

10.1

5.4

7.9

4.5

7.2

4.3

  Severe

1.2

0.3

1.2

0.6

0.8

0.2

Joint painÞ

  Any

21.9

13.6

16.7

9.1

16.0

8.9

  Mild

11.8

8.3

8.4

5.0

8.9

5.5

  Moderate

8.7

4.6

7.5

3.4

5.9

3.0

  Severe

1.4

0.7

0.8

0.7

1.2

0.4

Use of antipyretic medication

20.7

10.4

13.6

8.9

12.7

6.8

Table 6: Percentages of Subjects 18 through 25 Years of Age (Study 1016*) Reporting Systemic Adverse Reactions and Use of Antipyretic Medications Within 7 Days After Each Vaccination
Dose 1Dose 2Dose 3
Trumenba†Saline†Trumenba†Saline†Trumenba†Saline†
Systemic ReactionN=2425N=798N=2076N=706N=1823N=624
*
Study 1016: NCT01352845.
†
Trumenba was administered at 0, 2, and 6 months. Saline was administered at 0, 2, and 6 months.
‡
Study 1016: Fever (≥38°C): N=2415, 2067, and 1814 for Trumenba at Dose 1, Dose 2, and Dose 3, respectively; N=796, 705, and 621 for saline at Dose 1, Dose 2, and Dose 3, respectively.
§
Mild (1–2 times in 24 hours); moderate (>2 times in 24 hours); severe (requires intravenous hydration).
"Any" is defined as the cumulative frequency of subjects who reported a reaction as "mild", "moderate", or "severe" within 7 days of vaccination.
#
Mild (2–3 loose stools in 24 hours); moderate (4–5 loose stools in 24 hours); severe (6 or more loose stools in 24 hours).
Þ
Mild (does not interfere with activity); moderate (interferes with activity); severe (prevents daily activity).

Fever (≥38°C)‡

  ≥38.0°C

2.4

0.6

1.2

1.0

2.0

0.6

  38.0°C to <38.5°C

1.6

0.4

0.7

0.6

1.4

0.5

  38.5°C to <39.0°C

0.7

0.0

0.4

0.3

0.4

0.2

  39.0°C to ≤40.0°C

0.0

0.3

0.1

0.1

0.1

0.0

  >40.0°C

0.0

0.0

0.0

0.0

0.1

0.0

Vomiting§

  Any

2.6

2.1

2.1

1.6

2.0

1.4

  Mild

2.2

2.1

1.6

1.3

1.8

1.1

  Moderate

0.4

0.0

0.5

0.3

0.2

0.3

  Severe

0.0

0.0

0.0

0.0

0.0

0.0

Diarrhea#

  Any

12.7

11.8

8.6

8.1

7.5

6.9

  Mild

10.2

9.8

6.4

4.7

6.1

5.3

  Moderate

2.4

1.9

1.7

2.8

1.2

1.3

  Severe

0.2

0.1

0.5

0.6

0.2

0.3

HeadacheÞ

  Any

43.9

36.2

33.1

24.9

32.5

21.6

  Mild

24.3

22.1

18.4

13.6

17.6

12.5

  Moderate

17.9

13.5

13.3

10.1

13.3

8.3

  Severe

1.6

0.6

1.4

1.3

1.6

0.8

FatigueÞ

  Any

50.9

39.8

39.2

27.3

39.3

24.5

  Mild

25.4

23.2

20.6

13.9

18.9

13.1

  Moderate

22.1

15.8

16.4

11.5

18.8

9.6

  Severe

3.4

0.9

2.2

2.0

1.6

1.8

ChillsÞ

  Any

18.1

9.8

12.4

8.5

12.6

6.4

  Mild

12.0

8.1

8.1

6.9

7.7

4.3

  Moderate

4.9

1.6

3.5

1.6

4.2

2.1

  Severe

1.1

0.0

0.8

0.0

0.8

0.0

Muscle pain (other than muscle pain at the injection site)Þ

  Any

25.9

14.5

15.6

8.5

16.9

7.5

  Mild

13.0

9.6

7.6

5.8

8.9

4.5

  Moderate

11.3

4.4

7.1

2.3

6.8

2.9

  Severe

1.6

0.5

0.8

0.4

1.2

0.2

Joint painÞ

  Any

19.6

10.9

15.1

6.5

12.6

5.3

  Mild

10.3

6.9

8.1

3.7

6.6

2.9

  Moderate

7.9

3.5

6.2

2.5

5.4

2.4

  Severe

1.4

0.5

0.9

0.3

0.6

0.0

Use of antipyretic medication

13.4

8.9

12.3

7.6

12.8

6.6

In three early phase studies in which it was solicited, nausea was reported in up to 24% of adolescents.

The frequencies of adverse reactions were highest after the first dose regardless of the schedule. After subsequent doses, the frequencies of adverse reactions were similar regardless of dose number and schedule.

Serious Adverse Events

Among the 8 controlled studies investigating the three-dose (0, 1–2, and 6 months) schedule (Trumenba N=13,275, control N=5,501), SAEs were reported by 213 (1.6%) subjects and by 106 (1.9%) subjects who received at least one dose of Trumenba or control, respectively.

Non-serious Adverse Events

Among the 8 controlled studies investigating the three-dose (0, 1–2, and 6 months) schedule (Trumenba N=13,275, control N=5,501), AEs that occurred within 30 days of vaccination were reported in 4,056 (30.6%) subjects who received at least one dose of Trumenba and 1,539 (28.0%) subjects in the control group who received at least one dose. AEs that occurred at a frequency of at least 2% and were more frequently observed in subjects who received Trumenba than subjects in the control group were injection site pain, fever, and headache.

6.2 Postmarketing Experience

The following adverse reactions have been identified during post-approval use of Trumenba. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to product exposure.

Immune System Disorders: Hypersensitivity reactions, including anaphylactic reactions.

Nervous system disorder: Syncope (fainting).
Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.